FDA’s Fiscal Year 2027 Budget Is Chock-Full of Legislative Proposals – Especially on Hatch-Waxman and the BPCIA

Key Takeaways

• Domestic generics can file Paragraph IV a month earlier than foreign competitors
• All approved biosimilars will be deemed interchangeable, removing separate standard
• New abbreviated licensure pathway mirrors 505(b)(2) for biologics
• ANDA rules will explicitly cover drug‑device combination products
• Patent listing timing clarified for 30‑month stay eligibility

Pulse Analysis

The FDA’s FY2027 budget marks a pivotal shift in regulatory strategy, consolidating 27 legislative proposals that span food safety, tobacco control, and, most notably, drug and biologic approval processes. By embedding these initiatives directly into the budget justification, the agency signals a coordinated push to modernize statutes that have lagged behind scientific advances. The sheer volume of proposals—more than double the typical count—underscores Congress’s growing appetite for reforms that can both protect public health and stimulate domestic manufacturing, especially as the United States seeks to reduce reliance on foreign drug supplies.

From a Hatch‑Waxman perspective, the most consequential items are the early‑filing provision for domestic generics and the explicit treatment of drug‑device combination products. Allowing U.S. manufacturers to submit Paragraph IV certifications on the NCE‑1 date grants them a 30‑day advantage, effectively rewarding “America First” investments with the coveted 180‑day exclusivity period. Simultaneously, the amendment to section 505(j) clarifies FDA’s authority to review ANDAs that incorporate devices, a long‑standing bottleneck for complex products like auto‑injectors and inhalers. The clarification of the 30‑month stay tied to patent listing timing also reduces litigation uncertainty, giving innovators clearer expectations around market exclusivity.

On the biologics front, the budget proposes to dissolve the statutory distinction between biosimilar and interchangeable designations, automatically deeming approved biosimilars interchangeable. This aligns U.S. policy with the EU’s approach, potentially expanding pharmacy‑level substitution and driving down costs. The introduction of an abbreviated licensure pathway for biologics, modeled after the 505(b)(2) route for small‑molecule drugs, could accelerate entry of follow‑on biologics while preserving safety standards. Together, these reforms promise a more competitive market, faster patient access, and a stronger domestic supply chain, positioning the U.S. as a leader in modern drug regulation.